In the benign cohort, initial biopsies showed 37% of patients had ASAP with or without high-grade prostatic intraepithelial neoplasia (HGPIN), while 28% had HGPIN only, and 52% had neither ASAP or ...

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK ...

Nearly 4,000 participants came together on May 31 for We Walk UHNITED presented by Rogers, UHN Foundation's newest ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Researchers at the University of Michigan Rogel Cancer Center identified a gene that plays a key role in prostate cancer ...

Ameda, a leader in hospital-grade breast pump innovation, proudly announces the launch of the Ameda GLOtm Wearable Breast Pump, a compact, powerful, and truly hands-free solution designed with ...

Lentiviral interferon with immune checkpoint blockade: A novel method for gene therapy in bladder cancer. Activation of memory/effector T cells and association between prognosis and OX40-positive T ...

At a median follow-up of 60.7 months, patients in the combination arm of enzalutamide + leuprolide had significantly superior 5-year metastasis free survival rates (87.3% versus 71.4%; HR: 0.42, 95% ...

Dr. Alan Bryce presented the preliminary results from a phase II trial of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Late-line mCRPC patients have poor ...